Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Zanubrutinib Plus RCHOP (ZR-CHOP) in Newly Diagnosed Diffuse Large B-cell Lymphoma With Specific Gene Abnormality

NCT05290337 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05290337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05290337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Zanubrutinib Plus RCHOP (ZR-CHOP) in Newly Diagnosed Diffuse Large B-cell Lymphoma With Specific Gene Abnormality
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
January 4, 2022
Completion date
January 4, 2026
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma